Molecularly, strategies targeting TGF-β, which plays a central role in Treg induction and function, and GLS and other metabolic pathways, may effectively reverse the immunosuppressive effects of Tregs in HR+ BC. This evidence concerns the gene TGFB1 and breast cancer.